Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy

Status Active, not recruiting

Clinical Trial Summary

In this study we are looking at a type of radiation called proton radiation which is known to spare surrounding tissue and organs from radiation. The proton radiation will be delivered using 3D conformal proton radiation or scanned beam/IMPT (Intensity Modulated Proton Radiation Treatment). Proton radiation delivers no dose beyond the region requiring treatment. This may reduce side effects that patients would normally experience with conventional radiation therapy or other means of delivering proton radiation therapy. In this study we are evaluating the effectiveness of using proton radiation delivered to reduce side effects association with radiation treatment.

Clinical Trial Description

Proton radiation will be delivered daily for approximately 5 1/2 weeks. Patients will be assessed weekly for any side effects they may be experiencing. Patients will have follow-up visits 4 weeks after proton therapy ends, at 6 months, 12 months, and then every year for up to five years after treatment. Follow-up visits will include a physical examination, radiological imaging (if necessary), echocardiogram, and laboratory tests. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01340495
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	June 2011
Completion date	January 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03595592` - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer	Phase 3
Recruiting	`NCT05383196` - Onvansertib + Paclitaxel In TNBC	Phase 1/Phase 2
Recruiting	`NCT06158217` - Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Active, not recruiting	`NCT04448886` - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC	Phase 2
Completed	`NCT02773784` - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting	`NCT01509781` - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study	Phase 3
Completed	`NCT04478669` - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting	`NCT04553770` - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer	Phase 2
Recruiting	`NCT04677816` - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients	Phase 2
Terminated	`NCT01934335` - Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer	Phase 2
Completed	`NCT00507611` - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients	N/A
Completed	`NCT00581750` - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed	`NCT03304171` - Overall Diet Quality and Breast Cancer Risk	N/A
Completed	`NCT03709186` - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated	`NCT03361800` - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC	Early Phase 1
Recruiting	`NCT04648904` - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer	Early Phase 1
Recruiting	`NCT06328465` - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases	N/A
Active, not recruiting	`NCT03109522` - Axillary Reverse Mapping (ARM) Technique	N/A
Recruiting	`NCT03987555` - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting	`NCT03497702` - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer	Phase 2